Information Provided By:
Fly News Breaks for June 26, 2017
AMAG
Jun 26, 2017 | 14:36 EDT
Raymond James analyst Christopher Raymond noted that AMAG Pharmaceuticals' Makena auto-injector received a 10-month review, versus previous guidance for a six-month review, which he explains means that earliest market launch now cannot occur until after loss of orphan drug exclusivity. The analyst, who also fears this delay will not be the last for Makena, keeps an Underperform rating on AMAG shares.
News For AMAG From the Last 2 Days
There are no results for your query AMAG
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.